Thailand's Ministry of Public Health and MSD signed an MOU to advance the Medical Investment Hub policy across three pillars: medical service excellence, clinical research & development, and pharmaceutical/vaccine manufacturing. The initiative targets 0.5%+ GDP value addition, new foreign investment, and improving Thailand's health-competitiveness ranking from 56th to top 50 globally. Key focus areas include vaccine access (HPV, PCV), clinical research capacity building (targeting 2.5B baht investment by 2027), and voluntary licensing for HIV PrEP production domestically—signaling pragmatic public-private collaboration on health security and bioeconomy growth.